Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.51 |
| ▸ | F2 | P00734 | 7/20 | 0.48 |
| ▸ | KLK1 | P06870 | 2/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4605266 | 0.89 | F10 (0.48) | F10F2KLK1PLATALDH1A1 | |
| SCHEMBL2782337 | 0.86 | F10 (0.48) | F10F2KLK1PLATALDH1A1 | |
| SCHEMBL2782297 | 0.85 | F10 (0.47) | F10F2KLK1PLATALDH1A1 | |
| SCHEMBL2783308 | 0.81 | F10 (0.50) | F10F2KLK1PLATALDH1A1 | |
| SCHEMBL2779558 | 0.81 | F10 (0.49) | F10F2KLK1PLATALDH1A1 | |
| SCHEMBL5040232 | 0.80 | F10 (0.49) | F10F2KLK1PLAT | |
| SCHEMBL4606196 | 0.79 | F10 (0.46) | F10F2KLK1PLAT | |
| SCHEMBL4415806 | 0.78 | F10 (0.51) | F10F2KLK1PLATALDH1A1 | |
| SCHEMBL2781719 | 0.77 | F10 (0.48) | F10F2KLK1PLATNPC1 | |
| SCHEMBL2782382 | 0.77 | F10 (0.48) | F10F2KLK1PLATALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465806-B2 | Pyrrole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-16 | — | — | US | claimed |
| US-20070049573-A1 | Pyrrole-Derivatives as Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-01 | — | — | US | claimed |
| EP-1568698-A1 | Pyrrole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-08-31 | — | — | EP | claimed |
| US-7465806-B2 | Pyrrole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-16 | — | — | US | disclosed |
| US-20070049573-A1 | Pyrrole-Derivatives as Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
| EP-1725550-A2 | PYRROLE-DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085239-A2 | PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
| EP-1568698-A1 | Pyrrole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049573-A1 | Pyrrole-Derivatives as Factor Xa Inhibitors | F12, F2, F5 | F10 7/4885F2 2/4885KLK1 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.